271 related articles for article (PubMed ID: 11419183)
1. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
Smith MR; Joshi I; Jin F; Obasaju C
BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
[TBL] [Abstract][Full Text] [Related]
4. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
5. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
6. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma.
Carbone J; Perez-Fernandez R; Muñoz A; Sabin P; Carreño L; Fernandez-Cruz E
Clin Rev Allergy Immunol; 2008 Feb; 34(1):80-4. PubMed ID: 18270861
[TBL] [Abstract][Full Text] [Related]
9. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma.
Martinelli G; Laszlo D; Bertolini F; Pastano R; Mancuso P; Calleri A; Vanazzi A; Santoro P; Cavalli F; Zucca E
Br J Haematol; 2003 Oct; 123(2):271-7. PubMed ID: 14531908
[TBL] [Abstract][Full Text] [Related]
10. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
[TBL] [Abstract][Full Text] [Related]
11. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
13. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy.
Tsai DE; Schuster SJ; Matthies A; Moore HC; Alavi A; Juweid ME; Goldenberg DM; Stadtmauer EA
Clin Lymphoma; 2000 Jun; 1(1):62-6. PubMed ID: 11707815
[TBL] [Abstract][Full Text] [Related]
14. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.
Scott SD
Cancer Pract; 1998; 6(3):195-7. PubMed ID: 9652253
[TBL] [Abstract][Full Text] [Related]
18. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
19. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
[TBL] [Abstract][Full Text] [Related]
20. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
